Item 8.01 Other Events.

On June 30, 2009, Cephalon, Inc. (the "Company") announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval of NUVIGILŪ (armodafinil) Tablets
[C-IV] for the indication of improved wakefulness in patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel.
The Company hereby incorporates by reference the press release dated June 30, 2009, attached hereto as Exhibit 99.1, and made a part of this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description of Document
99.1 Press Release dated June 30, 2009

---